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TRPA1 and TRPV1 are crucial pain mediators, but
how their interaction contributes to persistent pain
is unknown. Here, we identify Tmem100 as a potenti-
ating modulator of TRPA1-V1 complexes. Tmem100
is coexpressed and forms a complex with TRPA1
and TRPV1 in DRG neurons. Tmem100-deficient
mice show a reduction in inflammatory mechanical
hyperalgesia and TRPA1- but not TRPV1-mediated
pain. Single-channel recording in a heterologous
system reveals that Tmem100 selectively potenti-
ates TRPA1 activity in a TRPV1-dependent manner.
Mechanistically, Tmem100 weakens the association
of TRPA1 and TRPV1, thereby releasing the inhibi-
tion of TRPA1 by TRPV1. A Tmem100 mutant,
Tmem100-3Q, exerts the opposite effect; i.e., it en-
hances the association of TRPA1 and TRPV1 and
strongly inhibits TRPA1. Strikingly, a cell-permeable
peptide (CPP) containing the C-terminal sequence
of Tmem100-3Q mimics its effect and inhibits
persistent pain. Our study unveils a context-depen-
dent modulation of the TRPA1-V1 complex, and
Tmem100-3Q CPP is a promising pain therapy.
INTRODUCTION
Pain is the cardinal symptom of many debilitating diseases,
causing heavy societal and health burdensworldwide. It is known
that ion channels and receptors in the dorsal root ganglia (DRG)
are responsible for the detection of noxious stimuli, and their
plasticity contributes to the increased severity of pain (Woolf
and Costigan, 1999). TRP (transient receptor potential) channels
are emerging targets for understanding this process and devel-oping novel treatments (VenkatachalamandMontell, 2007). Their
ability to form multimeric complexes (Goel et al., 2002; Hellwig
et al., 2005; Hofmann et al., 2002; Schaefer, 2005; Stru¨bing
et al., 2001; Xu et al., 1997) broadens the variety and complexity
of channel regulation and the potential implications for pain
modulation (Jeske et al., 2011; Liu et al., 2011; Patil et al., 2011;
Schmidt et al., 2009). Among TRP channels, TRPA1 and TRPV1
are essential and widely studied molecular sensors and media-
tors of pain signals inDRGneurons (Bautista et al., 2006;Caterina
et al., 2000; Caterina et al., 1997). It is well documented that most
if not all TRPA1+ DRG neurons coexpress TRPV1 (Bautista et al.,
2006; Story et al., 2003). Although recent studies have suggested
that TRPA1 and TRPV1 can form a complex in a heterologous
expression system as well as sensory neurons (Fischer et al.,
2014; McMahon and Wood, 2006; Salas et al., 2009; Staru-
schenko et al., 2010), the functional significance and modulation
of the complex in the nociceptive pathway are unclear.
We identified Tmem100 as a candidate for the modulation of
the TRPA1-V1 complex in the nociceptive pathway. Tmem100
is a 134-amino-acid, two-transmembrane protein highly con-
served in vertebrates (Moon et al., 2010). It is found in other
organs besides the DRG, expressed in blood vessels, ventral
neural tubes, and the notochord (Moon et al., 2010). Tmem100
has been shown to be involved in processes such as renal
development (Georgas et al., 2009), vasculogenesis (Moon
et al., 2010), and lung cancer cell invasiveness (Frullanti et al.,
2012). However, little is known about the underlyingmechanisms
of these effects and the role of Tmem100 in the nervous system.
Here, we demonstrate that Tmem100 enhances TRPA1 activ-
ity in vitro and in vivo. Interestingly, this regulation depends on
the presence of TRPV1. In the DRG, Tmem100 is coexpressed
with TRPA1 and TRPV1. It forms a complex with TRPA1 and
TRPV1 in both DRG neurons and heterologous systems.
Tmem100 selectively augments TRPA1-associated activity by
increasing the open probability of the channel when TRPA1
and TRPV1 are both present in membrane patches. Tmem100
mutant mice exhibit a reduction in inflammatory mechanicalNeuron 85, 833–846, February 18, 2015 ª2015 Elsevier Inc. 833
hyperalgesia and TRPA1- but not TRPV1-mediated pain. Mech-
anistically, Tmem100 weakens the association of TRPA1 and
TRPV1, thereby releasing the inhibition of TRPA1 by TRPV1
(Salas et al., 2009). A Tmem100 mutant, Tmem100-3Q, exerts
the opposite effect; i.e., it enhances the association of TRPA1
and TRPV1 and strongly inhibits TRPA1. Taking advantage of
this inhibition, we developed a new strategy for blocking persis-
tent pain. We designed a cell-permeable peptide that mimics the
C terminus of Tmem100-3Q and selectively inhibits TRPA1-
mediated activity and pain in a TRPV1-dependent manner.
RESULTS
Tmem100 Encodes a Two-Transmembrane Protein
Expressed in Peptidergic DRG Neurons
We investigated the topology of Tmem100 to understand its
cellular localization and distribution. Protein structure analysis
(PredictProtein, Columbia University, and SOSUI, Nagoya Uni-
versity, Japan) indicates that Tmem100 is a two-transmembrane
protein (Figure 1A). We transfected a Tmem100-myc construct
with c-myc at the C terminus into the F11 cell line and stained
with anti-myc antibody. Tmem100 was visualized at the plasma
membrane only after membrane permeabilization (Figures S1A
and S1C available online). Similar results were obtained with
anti-Tmem100 antibody against the N terminus (Figure S1B).
Staining also showed that the signal was primarily located in
the plasma membrane (Figure S1D). The data indicate that
Tmem100 is a two-transmembrane protein largely localized to
the plasma membrane with intracellular localization of both N
and C termini.
To characterize Tmem100-expressing DRG neurons, we
generated a knockin line in which the open reading frame of
Tmem100 was replaced with GFP (Tmem100GFP/+; Figures
S1E and S1F). Anti-Tmem100 antibody labeling confirmed that
GFP is specifically expressed in Tmem100+ DRG neurons in
the Tmem100GFP/+ mouse line (Figure S1F). Using GFP as a
marker, we found that Tmem100 was expressed in 24% of
lumbar DRG neurons (mainly small and medium in size) (Fig-
ure 1B). We double stained different DRG neuron markers with
GFP in the Tmem100GFP/+ line (Figures 1C, 1D, and S1G).
Ninety-five percent of Tmem100+ neurons express CGRP, and
88.4% of CGRP+ neurons express Tmem100. Both TRPA1 and
TRPV1 are coexpressed in a subset of Tmem100+ neurons. In
contrast, Tmem100+ neurons were rarely positive for IB4 (Figures
1C, 1D, and S1). These results suggest that Tmem100 is primar-
ily expressed in peptidergic DRG neurons (Figure 1E), many of
which are TRPV1 and TRPA1 double positive (Figure 1F) (Bau-
tista et al., 2006; Story et al., 2003). A recent study has shown
that TRPA1 is functionally expressed in IB4+ nonpeptidergic neu-
rons (Barabas et al., 2012). The culture conditions of dissociated
DRG neurons can influence the expression of TRPA1. On the
other hand, the sensitivity of anti-TRPA1 antibody may miss
the expression of TRPA1 in IB4+ neurons. Moreover, we found
a significant increase in the number of Tmem100-expressing
neurons in the DRG under inflammatory conditions induced by
complete Freund’s Adjuvant (CFA) injection (Figures S1H and
S1I). Collectively, the expression data suggest that Tmem100
may be involved in the modulation of pain.834 Neuron 85, 833–846, February 18, 2015 ª2015 Elsevier Inc.Selective Elimination of Tmem100 in Sensory Neurons
Leads to a Reduction of Mechanical Hyperalgesia and
TRPA1-Associated Nociception
Conditional knockout mice were generated to study the function
of Tmem100 in the nociceptive pathway (Tmem100fl/fl; Figure 2A)
because a global knockout of Tmem100 is lethal at E10.5
(Moon et al., 2010). Tmem100fl/fl mice were mated with male
Advillin+/CRE (Avil-Cre) mice to selectively eliminate Tmem100
in primary sensory neurons of the DRG (Hasegawa et al.,
2007). These mice were viable, and there were no obvious differ-
ences in gross appearance and behavior among wild-type (WT),
Avil-Cre;Tmem100+/+, Tmem100fl/fl, and Avil-Cre;Tmem100fl/fl
mice. The deletion of Tmem100 protein in the DRG was verified
by immunofluorescent staining andwestern blottingwith a rabbit
anti-Tmem100 antibody (Figures 2B and S2A). We did not
observe any significant changes in TRPA1 and TRPV1 expres-
sion in the DRG when Tmem100 was eliminated (Figures S2A–
S2C). Moreover, developmental and morphological phenotypes
were evaluated in the DRG and spinal cord from Avil-Cre;
Tmem100GFP/fl lines, and the results did not suggest any related
defects (Figures S2D–S2F).
We next determined whether Tmem100 plays a role in noci-
ception and hyperalgesia/allodynia by performing behavioral
tests on Tmem100 DRG conditional knockout mice, i.e., Avil-
Cre;Tmem100fl/fl (Tmem100 CKO). These mice exhibited normal
mechanical sensitivity under naive conditions (Figure 2C). How-
ever, Tmem100 CKO mice exhibited reduced acute nocifensive
behaviors induced by mustard oil (MO; an agonist of TRPA1
[Bautista et al., 2006; Kwan et al., 2006]) compared to Avil-
Cre;Tmem100+/+ and Tmem100fl/fl controls (Figures 2D and
S2G). TRPA1-dependent mechanical hyperalgesia generated
by injection of MO into mouse hindpaws (Bautista et al., 2006)
was also significantly decreased in Tmem100 CKO mice (Fig-
ure 2E). The average threshold for mechanically induced pain
was reduced to 0.06 g in both control groups and was signifi-
cantly higher (0.34 g) in Tmem100CKOmice. In the inflammatory
pain model generated by injection of CFA into the hindpaws,
Tmem100 CKO mice also showed attenuated mechanical
hyperalgesia (Figure 2G), consistent with a previous report on
the involvement of TRPA1 in inflammatory mechanical hyperal-
gesia (Petrus et al., 2007). The mechanical nociceptive threshold
was reduced to 0.18 and 0.11 g in Avil-Cre;Tmem100+/+ and
Tmem100fl/fl mice, respectively, but was 0.43 g in Tmem100
CKO mice at day 2. These data show that deletion of
Tmem100 in the DRG leads to a substantial reduction of inflam-
matory mechanical hyperalgesia and acute TRPA1-associated
nociception.
Interestingly, TRPV1-associated acute nociceptive behavior
and hyperalgesia remained relatively unperturbed in Tmem100
CKO mice. Tmem100 CKO mice did not show any significant
deficits in capsaicin-induced acute nocifensive behavior in the
hindpaw (Figure 2F). Tail immersion and hot plate tests also
failed to reveal any deficits in the mutant mice (Figures 2I and
2J). Furthermore, CFA-induced thermal hyperalgesia, which is
almost completely reversed after TRPV1 deletion but unaltered
after pharmacological blockade of TRPA1 (Caterina et al.,
2000; Petrus et al., 2007), was also unchanged in Tmem100
CKOmice (Figure 2H). We also tested cold-induced pain in these
Figure 1. Tmem100 Is Expressed in TRPA1-TRPV1-Positive Peptidergic DRG Neurons
(A) Postulated structure of Tmem100. Tmem100 is a two-transmembrane protein with a putative TRPA1 binding site (KRR) at its C terminus. Both the N and C
termini are intracellular, whereas the loop region is extracellular. PM, plasma membrane.
(B) Tmem100-expressing cells comprise 24% of L4-L6 DRG neurons. They are predominantly small-diameter, but medium- to large-diameter neurons are also
present. The average diameter of Tmem100-expressing neurons is 15.7 mm, and the median is 14.3 mm (DRG from three mice).
(C) Double staining of Tmem100-GFP with other DRG markers. Scale bar, 50 mm.
(D) Quantification of coexpression of Tmem100 and other DRG markers (DRG from three mice; data are presented as mean ± SEM).
(E and F) Diagrams showing the relationship of Tmem100 with other DRG markers. Tmem100 is a marker for the majority of CGRP+ DRG neurons (E); most
TRPA1+ DRG neurons express Tmem100 (F).animals, and the results suggest that this modality is not affected
by the elimination of Tmem100 (Figures S2H and S2I).
TRPA1-Mediated Responses Are Selectively Attenuated
in DRG Neurons from Tmem100 CKO Mice
To investigate the function of Tmem100 at a cellular level,
cultured DRG neurons from Tmem100 CKO mice were exam-
ined with calcium imaging and whole-cell electrophysiologyrecording. The results showed a selective reduction in TRPA1-
but not TRPV1- or TRPM8-mediated activities in the DRG neu-
rons when Tmem100 was deleted. In calcium imaging, only
IB4-negative DRG neurons were analyzed because the majority
of IB4+ neurons do not express Tmem100 (in cultured condi-
tions, only 4.8% ± 0.8% IB4+ neurons expressed Tmem100,
and 5.2% ± 0.5% of Tmem100+ neurons were IB4+; >900 neu-
rons from three mice were analyzed for each marker). TheNeuron 85, 833–846, February 18, 2015 ª2015 Elsevier Inc. 835
Figure 2. Tmem100 CKO Mice Show Selective Deficits in TRPA1-Associated Behaviors, whereas TRPV1-Associated Behaviors Are
Unaffected
(A) Tmem100 conditional KO strategy.
(B) Deletion of the Tmem100 gene in conditional KO lines was verified by anti-Tmem100 immunostaining of DRG. Scale bar, 50 mm.
(C) The baseline mechanical sensitivity of Tmem100 CKO (Avil-Cre;Tmem100fl/fl) mice is similar to that of the control group (Avil-Cre;Tmem100+/+ mice). At the
forces tested, there was no significant difference in the response rate among Tmem100 CKO and the control group (n = 10 for CKO and 13 for control).
(D) Tmem100 CKO mice showed decreased acute nocifensive behavior after 0.2%MO injection. White bar, Avil-Cre;Tmem100+/+; gray bar, Tmem100fl/fl; black
bar,Avil-Cre;Tmem100fl/fl. Total time of licking and flinching: 86 ± 6.2 s inAvil-Cre;Tmem100+/+; 86 ± 11.1 s in Tmem100fl/fl; 57 ± 9.3 s in Tmem100CKO; n = 13 for
Avil-Cre;Tmem100+/+ and Tmem100fl/fl ; n = 10 for Tmem100 CKO. *p < 0.05, **p < 0.01.
(E) Tmem100 CKO mice showed decreased mechanical hyperalgesia after MO injection (n = 11 for Avil-Cre;Tmem100+/+; 9 for Tmem100fl/fl ; 10 for Tmem100
CKO).
(F) Capsaicin-induced nocifensive behaviors (0.6 mg) are similar between Tmem100 CKO and the control group (Avil-Cre;Tmem100+/+mice). Time of licking and
flinching: 45 ± 5.7 s in Avil-Cre; Tmem100+/+ vs. 53.7 ± 8.3 s in Tmem100 CKO; n = 12 in CKO and 10 in control; p = 0.40).
(G and H) Tmem100CKOmice show decreasedmechanical hyperalgesia but intact thermal hyperalgesia after CFA injection. One and 2 days after CFA injection,
Tmem100CKOmice had highermechanical thresholds than both control groups, but the response to painful thermal stimuli remained unchanged (*p < 0.05; **p <
0.01; ***p < 0.001; n = 16 for Avil-Cre;Tmem100+/+; 10 for Tmem100fl/fl ; 18 for Tmem100 CKO for G; n = 9 for Avil-Cre;Tmem100+/+; 10 for Tmem100fl/fl ; 11 for
Tmem100 CKO for H).
(I and J) Nocifensive responses in the hot plate and tail immersion tests were intact in Tmem100 CKOmice. At the indicated temperatures, there was no difference
in the latency between CKO and control groups (Avil-Cre;Tmem100+/+ mice) (n = 9 and 13 for control and CKO, respectively, in I; n = 13 and 10 for control and
CKO, respectively, in J). All statistics are unpaired t tests except for (C), in which two-way ANOVA with Bonferroni’s post hoc test is used. Data are presented as
mean ± SEM.percentage of DRG neurons responsive to MO and the alterna-
tive TRPA1-specific agonist cinnamaldehyde (CA) was signifi-
cantly lower when Tmem100 was eliminated (Bandell et al.,
2004) (Figures 3A and S3A). Fourteen and 17% of DRG neurons
from Avil-Cre;Tmem100+/+ mice (i.e., controls) showed re-
sponses to MO and CA, respectively, and the percentages drop-
ped to 6% and 8% in the Tmem100 CKO group. Conversely, the
percentage of DRG neurons with TRPV1 activity remained
unchanged as 31% of IB4-negative DRG neurons responded
to capsaicin in both Avil-Cre;Tmem100+/+ and Tmem100 CKO
mice. We also used menthol as a control and observed no
difference in the percentage of neurons responsive to menthol,
which is mostly mediated by TRPM8 at this concentration (Bau-836 Neuron 85, 833–846, February 18, 2015 ª2015 Elsevier Inc.tista et al., 2006; Dhaka et al., 2007), between the control and
Tmem100 CKO neurons (Figure 3A).
Whole-cell patch-clamp recording of DRG neurons was car-
ried out to investigate regulation of TRPA1 and TRPV1-mediated
currents by Tmem100. The currents evoked by 7 and 25 mM
MO (based on the dose-response curve in Figure S3B) in
capsaicin (CAP)-responsive neurons were significantly smaller
in DRG neurons from Tmem100 CKO mice compared to Avil-
Cre;Tmem100+/+ neurons (Figures 3B and 3C). This finding
also showed that Tmem100 enhances TRPA1 activity.
We also examined the effect of Tmem100 on TRPV1-mediated
responses. CAP (100 nM)-evoked currents in DRG neurons were
not significantly different between Avil-Cre;Tmem100+/+ and
Figure 3. Tmem100 Enhances TRPA1-Mediated Responses in a
TRPV1-Dependent Manner
(A) TRPA1 activity in the DRG neurons of Tmem100 CKO mice was reduced,
whereas TRPV1 activity was relatively unchanged. The percentage of neurons
responding to 10 mMmustard oil (MO) and 250 mM cinnamaldehyde (CA) was
lower in the CKO line, whereas the percentage of neurons responding to
100 nM capsaicin (CAP) and 100 mM menthol were similar between the CKO
and control groups. (Each reagent was tested greater than three times in three
mice; greater than300 IB4cellswere assessed in theMO,CA, andCAPgroup,
and greater than 297 cells were assessed in the menthol group. All statistics
are unpaired t tests. The error bars represent SEM; *p < 0.05; **p < 0.01.)
(B) The average current induced by 7 or 25 mMMO (1 min application) is lower
in DRG neurons from Tmem100 CKO mice, whereas there is no significantTmem100 CKO mice (Figures 3D and 3E). Therefore, Tmem100
shows no modulatory effect on TRPV1 activity.
Tmem100 Enhances TRPA1 Activity in Heterologous
Expression Systems
Because both behavioral and cellular analyses suggest native
Tmem100 positively regulates TRPA1, we next asked if we could
reproduce a similar effect in a heterologous system. To mimic
the situations in wild-type and Tmem100/ DRG neurons, we
coexpressed TRPA1 and TRPV1 in CHO cells in the presence
or absence of Tmem100. MO-evoked whole-cell current density
and intracellular calcium accumulation were significantly higher
when Tmem100 was present with TRPA1 and TRPV1 (Figures
3F and 3G). A biotinylation assay revealed a trend of decreasing
TRPA1 levels (not statistically significant) on the plasma mem-
brane when wild-type Tmem100 was coexpressed with both
TRPV1 and TRPA1, whereas TRPV1 levels on the plasma mem-
brane remained unchanged (Figures S3D–S3F). Because the ef-
fect of Tmem100 on TRPA1 trafficking to the plasma membrane
is opposite that of its enhancement of channel activity, the true
effect of Tmem100 on the whole cell may be even stronger if
the lowering effect on membrane trafficking of the TRPA1 chan-
nel is taken into account.
To demonstrate that Tmem100’s actions can be reproduced in
an alternative heterologous expression system, we coexpressed
TRPA1 and TRPV1 in HEK293T cells. Tmem100 rendered 30%
and 20% of cells responsive to CA and MO, respectively,
whereas only 13% and 8% of cells responded to the same
agonist in the control group without Tmem100. Interestingly,
this enhancement was abolished when TRPV1 was replaced
by TRPM8 (Figures S3G and S3H), suggesting TRPM8 does
not have an inhibitory effect on TRPA1 as TRPV1 does. More-
over, Tmem100 also lowered the EC50 to CA by almost 3-fold
compared to the control group (Figure S3J). These results sug-
gest that Tmem100 selectively enhances TRPA1 activity at the
whole-cell level. Importantly, this positive effect requires the
presence of TRPV1.difference when 150 mMMO is applied. The numbers in the columns represent
the number of cells responding/ the number of cells tested. More than three
mice were tested from each group; all statistics are with unpaired t tests. All
error bars represent SEM; **p < 0.01.
(C) Representative traces of MO-induced currents from Avil-Cre;Tmem100+/+
and Avil-Cre;Tmem100fl/fl mice.
(D) The average current induced by 100 nM CAP (30 s application) is similar
among DRG neurons from Tmem100 CKO and control mice. The numbers in
the columns represent the number of cells responding/the number of cells
tested. More than three mice were tested from each group; all statistics are
unpaired t tests. The error bars represent SEM.
(E) Representative traces of CAP-induced currents from Avil-Cre;Tmem100+/+
and Avil-Cre;Tmem100fl/fl mice.
(F) MO (10 mM)-gated whole-cell voltage clamp (Vh = 60 mV) current den-
sities in TRPA1+TRPV1 (1:1)- and TRPA1+TRPV1+Tmem100 (1:1:4)-ex-
pressing CHO cells. The number of cells analyzed and those that responded
are indicated within bars. The statistic is an unpaired t test (**p < 0.01). Error
bars, SEM.
(G) MO (10 mM)-evoked Ca2+ influx into TRPA1+TRPV1 (1:1)- and TRPA1+
TRPV1+Tmem100 (1:1:4)-expressing CHO cells. The numbers of cells re-
sponding are indicated within bars. The statistic is an unpaired t test (***p <
0.001). Data are presented as mean ± SEM.
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Figure 4. Context-Dependent Regulation of Tmem100 in the TRPA1-V1 Complex
(A and B) MO (10 mM)- (A) and CAP (100 nM)-induced (B) single-channel open probability (Po) of the main conductance at Vh = 60 mV in CHO cells expressing
TRPA1 versus TRPA1+Tmem100 (T100) (1:4 molar ratio) and TRPA1+TRPV1 (1:1) versus TRPA1+TRPV1+Tmem100 (1:1:4). The configuration is cell-attached
patch, and the number of cells that responded among those analyzed is indicated within bars. The statistic is one-way ANOVA with Bonferroni’s post hoc test for
comparison between all columns (**p < 0.01; ***p < 0.001); error bars, SEM.
(C and D) Representative single-channel recording during 5 s at Vh = 60mV for MO-gated current (C) and 4 s for CAP-gated current (D) in TRPA1+TRPV1- and
TRPA1+TRPV1+Tmem100-expressing CHO cells; c is the closed state, o1, o2, and o3 show open states for three independent channels in the patch.
(E) Summary of data on single-channel conductance (pS) and effects on Po changes of Tmem100 (T100) for the given agonists and genes expressed. The values
of single-channel conductance were derived from Figure S4. Data are presented as mean ± SEM.Tmem100 Selectively Increases the Single-Channel
Open Probability of the TRPA1-V1 Complex to Mustard
Oil but Not Capsaicin
To analyze the effect of Tmem100 on TRPA1 and TRPV1 channel
properties, we performed cell-attached single-channel record-
ings. Using CHO cells expressing various combinations of
Tmem100, TRPA1, and TRPV1, we investigated open probabili-
ties (Po), single-channel activity (NPo), and conductance in
response to MO and CAP. The presence of TRPA1-V1 in the
recording patch was confirmed with single-channel responses
to both CAP and MO. When Tmem100 was coexpressed with
TRPA1 and TRPV1, a substantial increase was seen in the
TRPA1 Po; there was no increase in TRPA1 unitary single-chan-
nel conductance (Figures 4A, 4E, S3K, and S4E). The presence
of Tmem100 also caused a higher percentage of cells to respond
to MO and CA (Figures S3L and S3M). This modulation is not
a dose-dependent effect based on the ratio of Tmem100 to
TRPA1 or TRPV1 because the experiments with a different
transfection ratio of Tmem100 still yielded similar results (Fig-
ure S3I). Interestingly, coexpression of Tmem100 with TRPA1
in the absence of TRPV1 significantly reduced the TRPA1 Po
for both the main conductance and unitary single-channel838 Neuron 85, 833–846, February 18, 2015 ª2015 Elsevier Inc.conductance (Figures 4A, 4E, S4C, and S4E). Recordings of
TRPV1 and TRPA1, in both heterologous expression systems
and sensory neurons, exhibit multiple single-channel subcon-
ductance states (Nagata et al., 2005; Premkumar et al., 2002;
Staruschenko et al., 2010). This subconductance will influence
the whole-cell response; therefore, to examine the subconduc-
tance contributions, we also analyzed the effects of Tmem100
on single-channel activity (NPo) of TRPA1 and TRPV1. Fig-
ure S4A illustrates that Tmem100 regulates TRPA1 NPo in the
same way it affects Po; i.e., Tmem100 increases the TRPA1
NPo in the presence of TRPV1 and reduces its activity when
TRPV1 is absent.
TRPV1 single-channel Po and unitary conductance, as as-
sessed by the application of CAP, was relatively unaffected by
Tmem100 when TRPA1 was also present in patches (Figures
4B, 4E, and S4F). However, Tmem100 reduced single-channel
CAP responses in CHO cells expressing TRPV1 alone; this effect
was much weaker in DRG neurons (Figure S4K). Taken together,
these results suggest that Tmem100 requires TRPV1 to increase
intrinsic activity of TRPA1. Tmem100 inhibits the intrinsic activity
of individual TRPA1 and TRPV1 channels when the two are not
coexpressed.
Figure 5. Tmem100 Decreases the Interaction between TRPA1 and TRPV1, whereas the Tmem100-3Q Mutant Enhances It
(A) Co-IP with Tmem100 and TRPV1 antibodies and western blotting with TRPA1, TRPV1, and Tmem100 antibodies in mouse DRG lysates. Tmem100, TRPA1,
and TRPV1 form a complex in DRG neurons.
(B) Co-IP of TRPV1 and full-length myc-Tmem100 in TRPV1-expressing cells. The results show an interaction between Tmem100 and TRPV1.
(C) Co-IP of TRPA1 and full-length myc-Tmem100 in TRPA1-V1-coexpressing cells. Tmem100 binds TRPA1 at different dilutions.
(D) GST pull-downwith different TRPs and fragments of Tmem100 and Tmem100-3Qproteins. TRPV1 is pulled down by theC termini of bothWT Tmem100 (GST-
C-WT) and Tmem100-3Q (GST-C-3Q). It is also pulled down by the N terminus of WT Tmem100 (GST-N). However, TRPA1 is pulled down only by the C terminus
of WT Tmem100, whereas the Q-Q-Q mutation abolishes this interaction. The lysates from the cells expressing unconjugated GST (GST) and each TRP serve as
negative controls.
(E) FRET results with TIRF microscopy for the effects of Tmem100 on TRPA1-V1 interactions. All groups were transfected with TRPV1-CFP and TRPA1-YFP
except for the Rho-pYC (as a positive control for maximal effects of the system) and M-V1 (negative control) groups, where Rho-pYC and membrane-tethered
YFP + TRPV1-CFP, respectively, were transfected instead. FRET efficiencies were highest in Tmem100-3Q-transfected cells (A1-V1-3Q), followed by the empty
vector-transfected groups (A1-V1), and were lowest in cells transfected with wild-type Tmem100 (A1-V1-WT). The statistic is one-way ANOVA (*p < 0.05; **p <
0.01, ***p < 0.001). Data are presented as mean ± SEM.
(F) Summary of the data from (E).Tmem100 Binds Both TRPA1 and TRPV1
To test the possibility that the functional interaction of Tmem100
with TRPA1 and TRPV1 is due to a complex assembled in
sensory neurons, we performed coimmunoprecipitation (co-IP)
experiments from DRG lysates. The results show that Tmem100
forms complexes with endogenous TRPA1 and TRPV1 in mouse
DRG (Figure 5A). Furthermore, to investigate the contribution of
each protein to complex formation, we carried out co-IP experi-
ments using heterologous cells coexpressing Tmem100 with
either TRPA1 or TRPV1. Co-IP with full-length Tmem100-myc
suggested that Tmem100 forms complexes with TRPV1 and
TRPA1 individually (Figures 5B and 5C). Glutathione S-trans-
ferase (GST) pull-down studies using different fragments of
Tmem100 further characterized the distinct binding properties
of its N and C termini. We could pull down both TRPA1 and
TRPV1 separately with the C-terminal fragment of Tmem100;
however, the same conditions with the N terminus of Tmem100
only pulled down TRPV1 (Figure 5D). These results indicate that
Tmem100 can physically interact with TRPA1 and TRPV1.
We targeted the K-R-R sequence in the C terminus of
Tmem100 because of its positive charges and conservation
in vertebrates (Moon et al., 2010). To investigate the func-
tional significance of this sequence, we mutated it to an un-
charged Q-Q-Q sequence (Tmem100-3Q mutant). Interestingly,the Q-Q-Q mutation appeared to exert different effects on
TRPA1 and TRPV1 binding. For TRPA1, the binding was abol-
ished when the Q-Q-Q mutation was introduced to the C termi-
nus (GST-C-3Q). For TRPV1, this mutation did not appear to
weaken binding but instead enhanced it (Figures 5D, S5A, and
S5B). These data show that although the C terminus of
Tmem100 binds to both TRPA1 and TRPV1, its binding sites
to these two channels are different. Therefore, Tmem100-3Q
may exert distinct modulatory effects on TRPA1 and TRPV1
compared to wild-type Tmem100.
Wild-Type Tmem100 Weakens the Physical Association
of TRPA1-V1, whereas Tmem100-3Q Enhances It
Fo¨rster resonance energy transfer (FRET) and total internal
reflection fluorescence (TIRF) microscopy were used to search
for physical evidence of the modulatory mechanisms of
Tmem100 on the TRPA1-V1 complex. Cells coexpressing
TRPV1-CFP and TRPA1-YFP exhibited a significantly higher
FRET efficiency than cells coexpressing TRPV1-CFP and mem-
brane-tethered YFP (‘‘A1-V1’’ versus ‘‘M-V1’’ in Figure 5E). This
implies that TRPA1 and TRPV1 form a complex in the plasma
membrane. Strikingly, wild-type Tmem100 weakened the sur-
face TRPA1-V1 interaction, decreasing the FRET efficiency by
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TRPA1-V1. By contrast, the Tmem100-3Q mutant enhanced the
TRPA1-TRPV1 interaction by 43% (Figures 5E and 5F). These
data suggest that Tmem100 modulates the physical interaction
of the TRPA1-TRPV1 complex, with wild-type Tmem100 and
Tmem100-3Q exerting opposite effects on these interactions.
In a separate FRET-TIRF experiment, we found that the physical
interaction between TRPA1 and Tmem100 is further augmented
in the presence of TRPV1, whereas that of TRPV1 and Tmem100
is unaffected by TRPA1 (Figures S5C and S5D). In addition, the
interaction of TRPA1 and Tmem100 is weaker than that of
TRPV1 and Tmem100 (comparing ‘‘V1-T100’’ and ‘‘A1-T100’’
columns in Figures S5C and S5D). The FRET data suggest pref-
erential interactions between the three components. This result
also shows that the physical interaction among the three pro-
teins is not allosteric interaction but occurs via specific interac-
tion domains.
Tmem100-3Q Selectively Inhibits TRPA1-Mediated
Single Channel Activity in the TRPA1-V1 Complex
Further functional investigation of Tmem100-3Q revealed
that mutant Tmem100 has the opposite effect of wild-type
Tmem100 on TRPA1-mediated single-channel properties
at 60 mV (Figures 6A–6E and S6A–S6D). We found that,
in TRPA1-V1-coexpressing cells, Tmem100-3Q significantly
decreased single-channel MO-evoked Po with modest alter-
ations in unitary conductance (Figures 6A, 6E, and S6). Simi-
larly, whole-cell MO-activated current density was significantly
lower in TRPA1-V1-coexpressing cells containing Tmem100-
3Q than control cells without Tmem100-3Q (Figure 6F). Similar
results were obtained by calcium imaging assay (Figure 6G).
Tmem100-3Q also lowered the percentage of cells that re-
sponded to MO and CA in HEK293T cells expressing both
TRPA1 and TRPV1 (Figures S3L and S3M). UnlikeMO responses
in TRPA1-V1 cells, TRPV1-mediated single-channel activity
induced by CAP in TRPA1-V1 cells was relatively unchanged in
the presence of Tmem100-3Q (Figures 6B, 6D, and 6E).
Like wild-type Tmem100, Tmem100-3Q also exerts context-
dependentmodulatory effects on TRPA1 and TRPV1 homomers.
Tmem100-3Q reduced single-channel responses of cells ex-
pressing TRPV1 alone, whereas it had no effect on TRPA1 re-
sponses in cells containing only TRPA1 (Figures 6A and 6B).
CAP responses from TRPV1-expressing CHO cells showed
that the addition of Tmem100-3Q lowered its Po as well as
NPo (Figures 6B, S6B, and S6D). In contrast, no modulatory ef-
fect of Tmem100-3Q on TRPA1-mediated single-channel open
probability (Po) or activity (NPo) was observed in TRPA1-ex-
pressing cells (Figures 6A, S6A, and S6C). In summary, these
data suggest that Tmem100-3Q affects intrinsic and whole-cell
TRPA1 activity only in the presence of TRPV1.
Cell-Permeable Peptides Mimicking Tmem100-3Q
Attenuate TRPA1 Activity and Block Pain
To selectively attenuate TRPA1-mediated activity in both cellular
and behavioral studies, we utilized a cell-permeable peptide, an
approach that has been employed to effectively modulate intra-
cellular protein activity (Koren and Torchilin, 2012). We designed
and synthesized T100-Mut, a peptide that shares sequence with
the C terminus of Tmem100-3Q (Figure 7A). In addition, the N840 Neuron 85, 833–846, February 18, 2015 ª2015 Elsevier Inc.terminus of this peptide was conjugated with a myristoylated
group, which allows peptides to penetrate and localize to the
intracellular side of the plasma membrane (Nelson et al., 2007),
thereby mimicking the topology of Tmem100-3Q (Figure 8D).
At the cellular level, T100-Mut mimicked the effect of full-
length Tmem100-3Q by lowering TRPA1-mediated activity
in the TRPA1-V1 complex. T100-Mut pretreatment selectively
decreased responses to 10 mM MO in IB4-negative DRG neu-
rons (Figure 7B). However, the peptide had no effect on re-
sponses to 100 nM CAP in the same population (Figure 7B).
The results were largely consistent in a heterologous system.
T100-Mut treatment produced a 65% reduction in the percent-
age of cells responding to MO (Figure 7C). These results suggest
that T100-Mut mainly reduced TRPA1- but not TRPV1-associ-
ated activity. We also tested a cell-permeable peptide (CPP)
that shares sequence with the wild-type C terminus (T100-WT).
The result shows that T100-WT does not have a modulatory ef-
fect on TRPA1-V1 complexes (Figure 7C).
We next tested whether T100-Mut has a corresponding inhib-
itory effect on pain behaviors. T100-Mut-injected wild-type ani-
mals showed reduced MO-induced pain behavior (Figure 7D).
T100-Mut treatment significantly decreased acute nocifensive
behavior (36 ± 6 s) compared to the scrambled peptide-treated
group (80 ± 9 s). Mechanical hyperalgesia was also significantly
attenuated by T100-Mut (Figure 7D). However, T100-Mut did not
alter acute nocifensive behavior induced by CAP (Figure 7F).
Similar results were obtained in the CFA model: 3 hr after
T100-Mut treatment, mice showed attenuated mechanical but
not thermal hyperalgesia (Figure 7E). The mechanical thresholds
were significantly higher in the T100-Mut-treated group. The
level of thermal hyperalgesia remained similar between these
two groups. T100-Mut also alleviated mechanical hyperalgesia
induced by paclitaxel (Taxol), a commonly used chemothera-
peutic agent that produces TRPA1-dependent neuropathy as a
side effect (Materazzi et al., 2012) (Figure 7G). Furthermore, a
shortened CPP (called F2) consisting of the first 18 amino acids
of the T100-Mut could produce the same inhibitory effects,
whereas two other shortened CPPs that spanned different re-
gions of the T100-Mut C terminus had no effect (Figures S7A
and S7B). Together, these data suggest that the first four amino
acids of the Tmem100 C terminus, i.e., ‘‘WKVR,’’ and the 3Qmu-
tations are essential for the inhibitory effect of TMEM100-3Q on
TRPA1 in the TRPA1-V1 complex and that this effect is likely
caused by an enhanced interaction of TMEM100-3Q with
TRPV1. Furthermore, there was no effect of T100-Mut on MO-
induced acute pain and mechanical hyperalgesia in TRPV1/
mice (Figures 7H and 7I). We also compared the effects of
T100-Mut and HC-030031, a direct TRPA1 antagonist (Eid
et al., 2008), and found that T100-Mut showed comparable or
better efficacy and potency of inhibiting neuropathic pain as
the TRPA1 antagonist (Figures S7C and S7D). These behavioral
data demonstrate that T100-Mut selectively alleviates TRPA1-
associated pain and that this effect is TRPV1 dependent.
DISCUSSION
Functional interaction between TRPV1 and TRPA1 can occur
in several ways (Julius, 2013). TRPV1 and TRPA1 can modulate
Figure 6. Context-Dependent Regulation of Tmem100-3Q Mutant in the TRPA1-V1 Complex
(A and B) MO (10 mM)- (A) and CAP (100 nM)-induced (B) single-channel open probability (Po) of the main conductance at Vh = 60 mV in CHO cells expressing
TRPA1 versus TRPA1+Tmem100-3Q (T100-3Q) (1:4 molar ratio) and TRPA1+TRPV1 (1:1) versus TRPA1+TRPV1+Tmem100-3Q (1:1:4). The statistic is one-way
ANOVA as in Figure 4; *p < 0.05; **p < 0.01; NS, no significant difference.
(C and D) Representative single-channel recording traces at Vh = 60 mV for MO- (C) and CAP-gated (D) current in TRPV1+TRPA1- versus TRPV1+TRPA1+
Tmem100-3Q-expressing CHO cells. Traces are 4 s long.
(E) Summary of data on single-channel conductance (pS) and effects on Po changes of Tmem100-3Q for the given agonists and genes expressed. The values of
single-channel conductance were derived from Figure S4.
(F) MO (10 mM)-gated whole-cell voltage clamp (Vh = 60mV) current densities in TRPA1+TRPV1 (1:1)- and TRPA1+TRPV1+Tmem100-3Q (1:1:4)-expressing
CHO cells. Results: 138.9 ± 29.92 pA/pF for TRPA1+TRPV1 versus 39.16 ± 12.5 pA/pF for TRPA1+TRPV1+Tmem100-3Q cells. The statistic is an unpaired t test
(**p < 0.01).
(G) MO (10 mM)-evoked Ca2+ influx into TRPA1+TRPV1 (1:1)- and TRPA1+TRPV1+Tmem100-3Q (1:1:4)-expressing CHO cells. Results: 463.1 ± 26.8 nM for
TRPA1+TRPV1 versus 321 ± 18.2 nM for TRPA1+TRPV1+Tmem100-3Q cells. The numbers of cells responding/tested are indicatedwithin bars. The statistic is an
unpaired t test (***p < 0.001). Data are presented as mean ± SEM.each other’s activity by activating intracellular pathways. For
example, activation of TRPA1 can cause Ca2+ influx, triggering
Ca2+-dependent phosphatases, which, in turn, desensitize
TRPV1 activity (Akopian et al., 2007). Alternatively, TRPA1-initi-
ated Ca2+ influx could promote protein kinase A activity,
sensitizing TRPV1 channels (Spahn et al., 2014). Behavioralexperiments demonstrated that TRPA1 activation by MO leads
to functional desensitization of TRPV1 responses in vivo (Jac-
quot et al., 2005; Ruparel et al., 2008). Similarly, activation of
TRPV1 can lead to reduction of TRPA1 activity in vitro and in vivo
(Akopian et al., 2007; Jacquot et al., 2005; Ruparel et al.,
2008). An important element of these functional TRPV1-TRPA1Neuron 85, 833–846, February 18, 2015 ª2015 Elsevier Inc. 841
Figure 7. T100-Mut Cell-Permeable Peptide, T100-Mut, Alleviates TRPA1-Associated Pain
(A) Sequences of the cell-permeable peptide T100-Mut, scrambled peptide, T100-WT, and WT C-terminal sequence of Tmem100 (WT). Myr, myristoylation.
(B) Calcium imaging data from the T100-Mut-treated (200 nM) DRG neurons. (MO: 12% ± 1.3% in scrambled versus 4.6% ± 0.9% in T100-Mut-treated group;
CAP: 16% ± 1.3% in scrambled versus 15% ± 6.5% in T100-Mut; DRG from three mice).
(C) Calcium imaging data from HEK293T cells expressing TRPA1 and TRPV1. Pretreatment of T100-Mut (200 nM) reduced the percentage of cells responsive to
500 nMMO, whereas T100-WT produced no such effect (18% ± 2.8% in scrambled, 6% ± 2.4% in T100-Mut, and 17% ± 0.6%, repeated three times, *p < 0.05).
(D) Pretreatment with T100-Mut (5 ml of 2 mM) alleviated MO-induced acute nocifensive behavior (n = 6, **p < 0.01) and mechanical hyperalgesia (0.1 ± 0.03 g in
scrambled versus 0.4 ± 0.11 g in T100-Mut; n = 13, *p < 0.05).
(E) Pretreatment with T100-Mut (5 ml of 2 mM) alleviated CFA-inducedmechanical hyperalgesia (0.05 ± 0.0 g in scrambled versus 0.43 ± 0.1 g in T100-Mut; n = 10,
***p < 0.001) but not thermal hyperalgesia (3.9 ± 0.6 s in scrambled versus 4.3 ± 0.5 s in T100-Mut; n = 10, p = 0.63).
(F) Acute nocifensive behaviors induced by intradermal capsaicin injection (0.6 mg) were similar among the T100-Mut- and scrambled peptide-treated (2 mM)WT
mice (70 ± 11 s in scrambled versus 65 ± 9 s in T100-Mut; n = 8, p = 0.73).
(G) In wild-type mice injected with paclitaxel (Taxol), mechanical hyperalgesia was observed at day 7 postinjection. Hyperalgesia was attenuated by the intra-
dermal injection of T100-Mut (n = 7 for scrambled control peptide (open bar); n = 8 for T100-Mut peptide (black bar); *p < 0.05).
(H and I) In TRPV1/mice, T100-Mut did not perturb MO-induced acute pain (H) and mechanical hyperalgesia (I), as observed in WT mice. (n = 8, p = 0.91 for H
and 0.64 for I). All statistics are unpaired t tests and data are presented as mean ± SEM.interactions is that the channels need to be activated
sequentially.
An alternative mechanism would be the interaction of TRPV1
and TRPA1 within a complex. Indeed, a large body of evidence
indicates that TRP channels are capable of assembling into
channel complexes (Schaefer, 2005; Stru¨bing et al., 2003). Phys-
ical interaction within TRP complexes may alter the conforma-
tion of channels and thus influence the biophysical and regulato-
ry properties of each TRP channel (Xu et al., 1997). It was
demonstrated that TRPV1 and TRPA1 can form a complex in
heterologous expression systems and sensory neurons (Akopian
et al., 2007; Fischer et al., 2014; Staruschenko et al., 2010). For-
mation of such a complex can strongly influence the properties
of TRPA1 (Patil et al., 2011; Salas et al., 2009). The composition
and function of TRPV1-TRPA1 complexes in sensory neurons is
not yet clear. Requirement of TRPV1 activity for regulation within
the complex is unknown too.
Our studies propose a putative TRPA1-V1 complex model
in which a membrane adaptor protein, Tmem100, regulates the
physical association between TRPA1 and TRPV1 (Figure 8).842 Neuron 85, 833–846, February 18, 2015 ª2015 Elsevier Inc.Our and previous studies demonstrate that TRPA1 activity is
inhibited by TRPV1 when the two channels are coexpressed in
the absence of Tmem100 (Figures 4A and 8A) (Salas et al.,
2009). When Tmem100 is present, TRPA1 activity is potentiated
in a TRPV1-dependent fashion (Figures 2, 3, and 4). The pres-
ence of Tmem100 weakens the TRPA1-V1 association by phys-
ical interaction with both channels (Figures 5E and 8B), which
results in disinhibition of TRPA1 and a net-positive effect on
TRPA1-associated activity in the TRPA1-V1 complex. Moreover,
Tmem100-3Q (with stronger interactionwith TRPV1 and no inter-
action with TRPA1; Figures 5 and S5) exerts the opposite effect,
tightening the physical association between TRPA1 and TRPV1
(Figure 5E); TRPA1 inhibition by TRPV1 is increased (Figures
8C and 8D). The uniqueness of Tmem100 is that it not only pro-
vides a feasible model of regulation for TRPA1-V1 complexes,
but also demonstrates selectivity and context dependency.
Tmem100 preferentially augments the responses to TRPA1
agonists in the TRPA1-V1 complex, whereas the responses to
TRPV1 agonists remain relatively unchanged. This phenomenon
is consistent from single channels all the way to the behavioral
Figure 8. Model for the Modulatory Effects
of TRPV1 on TRPA1
Model for the modulatory effects of TRPV1 on
TRPA1 alone (A), WT Tmem100 (B), Tmem100-3Q
(C), and T100-Mut CPP (D) (with myristoylated
group inserted into the plasma membrane as
shown by the orange wiggly line). The distance
between TRPA1 and TRPV1 represents the de-
gree of association (the smaller the distance, the
stronger the association). The number of minus
signs and the size of the green arrows represent
the relative strength of inhibition of TRPA1 by
TRPV1.level. Electrophysiological and biochemical results indicate
that Tmem100 is able to physically associate with TRPA1 and
TRPV1 alone and modulate them. However, these regulatory
effects are inhibitory in nature for both TRPA1 and TRPV1 homo-
mers. Interestingly, the inhibitory effects of Tmem100 were
not observed in DRG neurons and behavioral assays. One
possible explanation is that most TRPA1+ DRG neurons also
express TRPV1; therefore, the amount of TRPA1 homomer could
be minimal in DRG neurons in either normal or pathological
conditions (Diogenes et al., 2007). An alternate possibility is
that Tmem100 modulates channels other than the TRPA1-V1
complex and contributes to other phenotypes (Somekawa
et al., 2012). We did not investigate the modulatory effects of
Tmem100 on TRPV1 responses in DRG neurons and behaviors,
although the data from a heterologous expression system
suggested that Tmem100 may inhibit CAP-mediated responses
in TRPV1+/TRPA1 DRG neurons. One explanation is that
Tmem100 has low expression levels in the TRPV1+/TRPA1
neuronal subset (Figure 1). Further investigation is required to
test this possibility.
The discovery of Tmem100 also reconciles the inconsistent ef-
fects of TRPV1 on TRPA1-mediated currents reported in native
sensory neurons versus heterologous systems (Salas et al.,
2009). MO-induced currents were smaller in sensory neurons
from TRPV1/mice. This is in contrast to the expected increase
in currents because TRPV1 inhibits TRPA1 in heterologous sys-
tems. Our data provide an explanation for the underlying mech-
anisms. In Tmem100/ DRG neurons, as seen in the heterolo-
gous system, TRPA1-mediated activity was lowered compared
to Tmem100+/+ neurons, presumably due to the inhibitory effect
of TRPV1. Our heterologous studies show that Tmem100 itself
also inhibits TRPA1 activity in the absence of TRPV1 (compare
the ‘‘A1’’ and ‘‘A1+T100’’ columns in Figures 4A and S4A).
Because TRPA1+ sensory neurons from TRPV1/ mice still ex-
press Tmem100, the MO-gated currents would be inhibited byNeuron 85, 833–846,Tmem100. This inhibition is exactly what
previous studies (Salas et al., 2009) and
ours (compare the open bars in Figures
7D and 7H) have found in TRPV1/
DRG neurons andmice. Therefore, taking
into account the modulatory action of
Tmem100, the data collected from heter-
ologous cells and native neurons are now
consistent and suggest that the interac-tion between TRPV1 and TRPA1 leads to an inhibition of
TRPA1 by TRPV1.
Several lines of evidence indicate that Tmem100 plays an
important role in pain and inflammation. First, treatment
with NSAIDs and immunosuppressants reduces its expression
(Yamazaki et al., 2011). Second, inflammatory pain is reduced
in Tmem100 sensory neuron-specific knockout mice. Third,
Tmem100 is exclusively expressed in peptidergic DRG neurons,
which are crucial for neurogenic inflammation (Figure 1H). Last,
TRPA1 and TRPV1, both key targets of Tmem100 modulation,
are critical regulators of inflammatory pain (Bautista et al.,
2006; Caterina et al., 2000). Thus, an approach that interferes
with this pathway will provide specificity to control pain under
pathological conditions and may consequently be important in
pain management.
The discovery and subsequent characterization of the T100-
Mut cell-permeable peptide is a promising avenue for the
management of pain. The extent of the inhibitory effect of
T100-Mut is comparable to that of other potent TRPA1 antag-
onists (da Costa et al., 2010; McNamara et al., 2007; Petrus
et al., 2007). The major advantage of this approach is to maxi-
mize the specificity and thus minimize the possible side ef-
fects of drugs by specifically targeting the TRPA1-V1 complex
instead of TRP homomers expressed in other tissues. There-
fore, further research on Tmem100 may lead to a better under-
standing of the processing, modulation, and management of
pain.
EXPERIMENTAL PROCEDURES
Molecular Biology and Biochemistry
Generation of Tmem100 GFP Knockin Mouse Line
Full-length Tmem100 cDNA from mouse DRG was cloned into the pGEM
T-Easy vector (Promega) and later subcloned into the expression vector
pcDNA3.1. The gene deletion constructs eliminated exon 3, which con-
tains the entire coding region of Tmem100. Tmem100GFP/+ mice wereFebruary 18, 2015 ª2015 Elsevier Inc. 843
generated using the targeting construct by the Transgenic Core Labora-
tory at the Johns Hopkins University. See Supplemental Information for
details.
Generation of Tmem100 Conditional Knockout Mice
A BAC clone containing the entire Tmem100 genomic sequence was pur-
chased from Children’s Hospital Oakland Research Institute and modified
by recombineering (Liu et al., 2003). The final gene targeting vector contains
exon 3 and a PGK-Neo cassette flanked by two loxP sites. For the behav-
ioral studies, mice were crossed with WT C57/BL6 for more than five gen-
erations before mating to an Avil+/CRE line. See Supplemental Information
for details.
Generation of Tmem100 Constructs
The DNA fragments corresponding to the N- (1–43) and C- (110–134) terminal
regions of Tmem100 were generated by PCR amplification of Tmem100 cDNA
and subcloned into the pCMV-GST vector in frame with glutathione S-trans-
ferase (GST). The mutant forms of full-length and C terminus of Tmem100
were generated using the QuikChange Site-Directed Mutagenesis Kit
(Stratagene).
Anti-Tmem100 Serum
Rabbit polyclonal antibodywas raised and purified against a synthetic peptide,
TEESTKENLGAPKSPTPVTC, corresponding to the N terminus of mouse
Tmem100 by Proteintech Group.
Western Blot of DRG Lysate
DRG from cervical to lumbar levels were collected in 300 ml PBS and 2% SDS
with protease inhibitor (Sigma P8340). The primary antibodies used were:
1:5,000 anti-Tmem100, 1:1,000 anti-TRPV1 (Santa Cruz Biotechnology,
R130), and 1:1,000 anti-TRPA1 (Novus, NB110-40763). Secondary anti-
bodies for visualization included donkey ant-rabbit and anti-mouse HRP-con-
jugated antibodies (GE Biosciences). See Supplemental Information for
details.
Coimmunoprecipitation
DRG from all levels or CHO cells transfectedwith Trpv1, Trpa1, and Tmem100-
myc were used. Whole-cell DRG or CHO cells lysates were generated 24 hr
after transfection and Co-IP with either 1 mg myc antibody (EMD Millipore) or
1 mg TRPV1 antibody (Santa Cruz, R130) as described (Akopian et al., 2007).
See Supplemental Information for details.
GST Pull-Down
The GST-N, GST-C fusion, and GST constructs (2 mg) were individually trans-
fected with 2 mg of Trpa1, Trpv1, Trpm8, and Trpv2 constructs into HEK293T
cells with Lipofectamine 2000. The supernatants were incubated with gluta-
thione-agarose beads (GE Bioscience). See Supplemental Information for
details.
Behavioral Assays
Two- to four-month-oldmalemice backcrossed to C57Bl/6mice for more than
five generations were tested. All experiments were performed with the proto-
cols approved by the Animal Care and Use Committee of Johns Hopkins Uni-
versity School of Medicine and University of Texas Health Science Center, San
Antonio. Themice were housed in the vivariumwith 12-hr-light/dark cycle, and
all the behavioral tests were performed from 9 a.m. to 2 p.m. in the light cycle.
The housing group was 5 at maximum. The behavioral assays were performed
with the personnel blinded to the genotypes or peptides injected. See Supple-
mental Information for details.
Calcium Imaging
Calcium imaging assays were performed as previously described (Liu et al.,
2009). Cells were loaded with 2 mM fura 2-acetomethoxy ester (Molecular
Probes) for 30 min in the dark at room temperature or for 45 min at 37C for
DRG and cell lines, respectively. Intracellular calibration for calcium was per-
formed as previously described (Akopian et al., 2007). The data were analyzed
with the experimenter blinded to the genotypes or constructs transfected. See
Supplemental Information for details.
Cell Culture
The DRG neurons were cultured as previously described (Liu et al., 2009).
HEK293T, COS-7, and CHO cells were cultured in a medium consisting of
90% DMEM, 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin. Neu-844 Neuron 85, 833–846, February 18, 2015 ª2015 Elsevier Inc.rons were tested within 24 hr after plating onto the coverslips. See Supple-
mental Information for details.
Electrophysiology
Recordings were made in cell-attached single-channel or whole-cell voltage
clamp configurations at 22C –24C from the somata of small-to-medium
mouse DRG neurons (15–35 pF) or CHO cells. The baseline activities of the
cells were recorded for 1–2 min prior drug applications. The durations of
drug applications are noted in legends to figures. Single-channel analyses of
traces were performed from the 10th to 30th s after commencing drug applica-
tions. See Supplemental Information for details.
Immunofluorescent Staining
Adult mice of 8–12 weeks old were anesthetized with pentobarbital and
perfused with 20 ml 0.1 M PBS (pH 7.4; 4 degrees) as previously described
(Kim et al., 2008) followed with 25 ml 4% paraformaldehyde and 14%
picric acid in PBS (4 degrees). Images were obtained using the Zeiss
LSM700 confocal microscope system. See Supplemental Information for
details.
Live Staining
F11 cell line was transfected with 0.6 mg of either pcDNA3.1-Tmem100-myc or
pcDNA3.1-Tmem100 +0.2 mg mCherry following Lipofectamine 2000 protocol.
The samples were incubated with primary antibodies (1:200mouse anti-c-myc
ab, 9B11) or 1:1,000 rabbit anti-Tmem100 antibody. They were incubated with
secondary antibodies (1:1,000 goat anti-mouse immunoglobulin G [IgG]-488
[Invitrogen] or goat anti-rabbit IgG-488 [Invitrogen]). See Supplemental Infor-
mation for details.
Total Internal Reflection Fluorescence Microscopy and Fo¨rster
Resonance Energy Transfer
Expression vectors of pEYFP-TRPA1 (YFP on C-terminal part), pECFP-TRPV1
(CFP on C-terminal part), and pEYFP-N1 were transfected into COS-7 cells
with FuGENE HD (Promega E2311), as previously described (Staruschenko
et al., 2010). COS-7 cells were chosen because they have flat morphology
and thus suitable for TIRF-FRET analysis. Moreover, previously it has been
shown that CHO and COS cells express TRPA1 and TRPV1 to the same level
(Staruschenko et al., 2010). Data from fixed cells were collected in separate fa-
cilities at University of Texas Health Science Center, San Antonio, and the
Johns Hopkins University, respectively. See Supplemental Information for
details.
Cell-Permeable Peptides
The sequence from the last 28 amino acids of the C terminus of the Tmem100-
3Q mutant protein was synthesized and myristoylated at its N terminus (myr-
WKVRQRNKKVQQQESQTALVVNQRCLFA-COOH) by Twentyfirst Century
Biochemicals. The scrambled peptide was synthesized with the same compo-
sition and did not resemble any known protein (myr-QRVLEQVLQNWSR
RANVKQAQKFQVKCT – COOH). For the rat behavior assays, human T100-
3Q (h-T100), a palmitoylated cell-permeable peptide mutated based on the
C terminus of human sequence in Tmem100, was used; the sequence is Pal-
mitoyl-WKVRQRSKKAQQQESQTALVANQRSLFA-COOH. See Supplemental
Information for details.
Statistical Analysis
Error bars are presented as mean ± SEM. Numerical data in the text are pre-
sented as mean ± SEM n represents the number of mice, individual respond-
ing cells, or individual tests analyzed. Statistical comparisons between two
groups were conducted by two-tailed, unpaired Student’s t test. Multiple
groups were compared and analyzed by using one-way ANOVA and Bonfer-
roni’s post hoc test (where each column was compared to all other columns).
Differences between groups with genotype and time as factors were ac-
cessed by two-way ANOVA with Bonferroni’s multiple comparison post hoc
tests. Power analysis was used to justify the sample size. Differences were
considered as statistically significant for p < 0.05. Representative data are
from experiments that were replicated biologically at least three times with
similar results.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.neuron.2014.12.065.
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